Cagrilintide
Long-Acting Amylin Analogue
Best For
Metabolic protocols seeking GLP-1-independent pathways, combination weight management strategies
Amylin
Receptor pathway activated
1x/wk
Dosing frequency (long-acting analogue)
Additive
Effect when combined with GLP-1 agonists
How It Works
Cagrilintide is an acylated, long-acting analogue of the pancreatic hormone amylin, engineered for once-weekly dosing. It activates amylin receptors in the area postrema and nucleus of the solitary tract, inducing satiety signals that reduce caloric intake independently of the GLP-1 pathway. Cagrilintide also slows gastric emptying, contributing to prolonged post-meal fullness. Research suggests its mechanism is complementary to GLP-1 receptor agonists, which is why combination protocols (e.g., CagriSema) have shown additive weight reduction in clinical trials.
Key Research Areas
Satiety Signaling
Activates amylin receptors in the area postrema to reduce hunger independently of GLP-1
Gastric Regulation
Slows gastric emptying for sustained post-meal satisfaction
GLP-1 Synergy
Complementary mechanism produces additive effects when combined with incretin therapies
Weekly Dosing
Acylated design enables long-acting, once-weekly administration
Research Highlights
- Amylin-pathway satiety — complementary to GLP-1 receptor agonists
- Long-acting acylated design supports convenient once-weekly dosing
Formulation Notes
Common concentrations referenced in published clinical studies:
[CGL5]5mg[CGL10]10mgCategory
GLP-1, GIP, and glucagon receptor agonists represent the most significant advance in metabolic medicine. These peptides ...
Explore Lean Body category →Educational Content. This compound profile is for informational purposes only. Not intended as medical advice, diagnosis, or treatment.
Related Compounds
Semaglutide
GLP-1 Receptor Agonist
- Most-studied GLP-1 agonist with over 10,000 participants across STEP trials
- Demonstrated cardiovascular benefit independent of weight loss
Reference Codes
[SM5]5mg[SM10]10mg[SM15]15mg[SM20]20mg[SM30]30mgCagriSema
Amylin + GLP-1 Dual Agonist
- First combination to pair amylin and GLP-1 agonism in a single protocol
- Additive weight loss beyond what either pathway achieves alone
Reference Codes
[CS10]10mg (Cagri 5mg + Sema 5mg)Tirzepatide
Dual GIP/GLP-1 Agonist
- Superior to single-agent therapies in every trial
- Activates two incretin pathways for broader metabolic impact
Reference Codes
[TR20]20mg[TR40]40mgEvidence reviewed: March 2026